Morris D L, Jeong H G, Jordan S D, Kaminski N E, Holsapple M P
Department of Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298, USA.
Arch Toxicol. 1998 Feb;72(3):157-68. doi: 10.1007/s002040050482.
Previous studies have demonstrated that repeated (14 day) administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) enhances the suppression of humoral immunity in DBA/2 (Ah-low responder) mice relative to the effect seen with identical cumulative doses after a single treatment (cumulative doses of 4.2, 14.0, and 42 mg/kg). In the present studies, we have explored this phenomenon further by determining the status of several specific parameters, which might account for the increase in antibody suppression in the DBA/2 strain following repeated TCDD exposures. Included in these studies was the induction of hepatic and splenic microsomal 7-ethoxyresorufin-o-deethylase (EROD; P4501A1) activity and biodistribution of the administered TCDD into various target organs and tissues. Changes in lymphocyte subpopulations within the spleen were also assessed by flow cytometry following both single and repeated dosing. All studies made use of direct comparisons between DBA/2 (Ah-low responder) and B6C3F1 (Ah-high responder) female mice. Results of these studies demonstrate that the enhanced suppression of humoral immunity in DBA/2 mice following repeated exposure to TCDD is not directly associated with increases in liver microsomal EROD activity and does not appear to be correlated with changes in the pattern of biodistribution or amount of TCDD within the liver or spleen of these animals. In contrast, the most significant changes that occurred following repeated dosing in either strain were observed in the levels of microsomal EROD activity and immune cell ratios within the spleen. This effect was characterized as an increase in microsomal EROD activity, and a corresponding reduction in the numbers of a non-B/non-T cell population in the spleen.
先前的研究表明,相对于单次给药后相同累积剂量(累积剂量为4.2、14.0和42 mg/kg)所产生的效果,重复(14天)给予2,3,7,8-四氯二苯并对二恶英(TCDD)会增强对DBA/2(Ah低反应者)小鼠体液免疫的抑制作用。在本研究中,我们通过确定几个特定参数的状态进一步探究了这一现象,这些参数可能解释了DBA/2品系小鼠在反复接触TCDD后抗体抑制作用的增强。这些研究包括诱导肝和脾微粒体7-乙氧基异吩恶唑酮-O-脱乙基酶(EROD;P4501A1)活性以及所给予的TCDD在各种靶器官和组织中的生物分布。在单次和重复给药后,还通过流式细胞术评估了脾内淋巴细胞亚群的变化。所有研究均对DBA/2(Ah低反应者)和B6C3F1(Ah高反应者)雌性小鼠进行了直接比较。这些研究结果表明,DBA/2小鼠在反复接触TCDD后体液免疫抑制作用的增强与肝微粒体EROD活性的增加没有直接关联,并且似乎与这些动物肝脏或脾脏内TCDD的生物分布模式或含量变化无关。相反,在任一品系中,重复给药后观察到的最显著变化是脾内微粒体EROD活性水平和免疫细胞比例的变化。这种效应的特征是微粒体EROD活性增加,以及脾脏中非B/非T细胞群体数量相应减少。